https://doi.org/10.4081/reumatismo.2022.1482

Reply to: “Herpes zoster seven days after SARS-CoV-2 vaccination in a patient with ankylosing spondylitis under adalimumab” by Josef Finsterer

Vol. 74 No. 1 (2022)
Published: 3 May 2022
Abstract Views: 2108
PDF: 520
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

B. Maranini
beatrice.maranini@edu.unife.it
Rheumatology Unit, Department of Medical Sciences, University of Ferrara, Italy.
G. Ciancio
Rheumatology Unit, Department of Medical Sciences, University of Ferrara, Italy.
R. Cultrera
Infectious Diseases, Department of Translational Medicine, University of Ferrara, Italy.
M. Govoni
Rheumatology Unit, Department of Medical Sciences, University of Ferrara, Italy.

Not available

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
Maranini B, Ciancio G, Cultrera R, Govoni M. Herpes zoster infection following mRNA COVID-19 vaccine in a patient with ankylosing spondylitis. Reumatismo. 2021; 73: 1445. DOI: https://doi.org/10.4081/reumatismo.2021.1445
Gershon AA, Breuer J, Cohen JI, et al. Varicella zoster virus infection. Nat Rev Dis Primers. 2015; 1: 15016. DOI: https://doi.org/10.1038/nrdp.2015.16
Marra F, Parhar K, Huang B, Vadlamudi N. Risk factors for herpes zoster infection: a meta-analysis. Open Forum Infect Dis. 2020; 7: ofaa005. DOI: https://doi.org/10.1093/ofid/ofaa005
Che H, Lukas C, Morel J, Combe B. Risk of herpes/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis. Joint Bone Spine. 2014; 81: 215-21. DOI: https://doi.org/10.1016/j.jbspin.2013.07.009
Ting SW, Ting SY, Lin YS, et al. Risk of herpes zoster in psoriasis patients receiving systemic therapies: a nationwide population-based cohort study. Sci Rep. 2021; 11: 11824. DOI: https://doi.org/10.1038/s41598-021-91356-3
Chiu YM, Tang CH, Hung ST, et al. A real-world risk analysis of biological treatment (adalimumab and etanercept) in a country with a high prevalence of tuberculosis and chronic liver disease: a nationwide population-based study. Scand J Rheumatol. 2017; 46: 236-40. DOI: https://doi.org/10.1080/03009742.2016.1202318
Khazan M, Nasiri S, Riahi SM, et al. Measurement of melatonin, indole-dioxygenase, IL-6, IL-18, ferritin, CRP, and total homocysteine levels during herpes zoster. J Med Virol. 2020; 92: 1253-9. DOI: https://doi.org/10.1002/jmv.25484
Bauer ME, Fuente Mde L. The role of oxidative and inflammatory stress and persistent viral infections in immunosenescence. Mech Ageing Dev. 2016; 158: 27-37. DOI: https://doi.org/10.1016/j.mad.2016.01.001
Tozzi AE, Asturias EJ, Balakrishnan MR, et al. Assessment of causality of individual adverse events following immunization (AEFI): a WHO tool for global use. Vaccine. 2013; 31: 5041-6. DOI: https://doi.org/10.1016/j.vaccine.2013.08.087
Psichogiou M, Samarkos M, Mikos N, Hatzakis A. Reactivation of varicella zoster virus after vaccination for SARS-CoV-2. Vaccines (Basel). 2021; 9: 6. DOI: https://doi.org/10.3390/vaccines9060572
Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020; 79: 39-52. DOI: https://doi.org/10.1136/annrheumdis-2019-215882
Bijlsma JW. EULAR December 2020 View points on SARS-CoV-2 vaccination in patients with RMDs. Ann Rheum Dis. 2021. [Epub ahead of print]. DOI: https://doi.org/10.1136/annrheumdis-2020-219773
Lenfant T, Jin Y, Kirchner E, et al. Safety of recombinant zoster vaccine: a retrospective study of 622 rheumatology patients. Rheumatology (Oxford). 2021; 60: 5149-57. DOI: https://doi.org/10.1093/rheumatology/keab139
FDA. Shingrix 2021. Available from: https://www.fda.gov/vaccines-blood-biologics/vaccines/shingrix
Yanni EA, Ferreira G, Guennec M, et al. Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000-2012. BMJ Open. 2018; 8: e020528. DOI: https://doi.org/10.1136/bmjopen-2017-020528
Curran D, Hunjan M, El Ghachi A, El-Hahi Y, Bianco V, Ferreira G. Herpes zoster related healthcare burden and costs in immunocompromised (IC) and IC-free populations in England: an observational retrospective database analysis. BMJ Open. 2019; 9: e023502. DOI: https://doi.org/10.1136/bmjopen-2018-023502
Munoz-Quiles C, Lopez-Lacort M, Diez-Domingo J, Orrico-Sanchez A. Herpes zoster risk and burden of disease in immunocompromised populations: a population-based study using health system integrated databases, 2009-2014. BMC Infect Dis. 2020; 20: 905. DOI: https://doi.org/10.1186/s12879-020-05648-6
Matthews I, Duong M, Parsons VL, et al. Burden of disease from shingles and post-herpetic neuralgia in the over 80 year olds in the UK. PLoS One. 2020; 15: e0229224. DOI: https://doi.org/10.1371/journal.pone.0229224
Chandler RE. Optimizing safety surveillance for COVID-19 vaccines. Nat Rev Immunol. 2020; 20: 451-2. DOI: https://doi.org/10.1038/s41577-020-0372-8
Machado PM, Lawson-Tovey S, Strangfeld A, et al. Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. Ann Rheum Dis. 2021. [Epub ahead of print]. DOI: https://doi.org/10.1136/annrheumdis-2021-221490

How to Cite

Maranini, B., Ciancio, G., Cultrera, R., & Govoni, M. (2022). Reply to: “Herpes zoster seven days after SARS-CoV-2 vaccination in a patient with ankylosing spondylitis under adalimumab” by Josef Finsterer. Reumatismo, 74(1). https://doi.org/10.4081/reumatismo.2022.1482
Copyright (c) 2022 the Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.